Latest News on Clinical Trials
Worldwide Clinical Trials Expands Executive Team with Key New Hire, Mike Mencer as EVP and General Manager, Early Phase Services
Worldwide Clinical Trials, Inc. (Worldwide), an award-winning, full-service, midsize, global contract research organization (CRO), announced today that Mike Mencer has joined the company as the EVP and General Manager of Worldwide’s Early Phase Services, focusing on...
The Cardiac & Vascular Institute First in Florida to Enroll Patients in New Clinical Trial Studying LimFlow Therapy
Gainesville, FL, February 20, 2020 --(PR.com)-- The Cardiac & Vascular Institute (TCAVI) announced it is the first in Florida to perform a successful procedure in the PROMISE II pivotal study of the LimFlow Percutaneous Deep Vein Arterialization System for the...
Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine
NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient...
Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet the Primary Endpoint
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Phase 2/3 ARTISTS 1 and Phase 3 ARTISTS 2 trials designed to evaluate deutetrabenazine compared to placebo for the treatment of tics in pediatric patients...
RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degeneration
TOKYO--(Business Wire)--RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced that first patient has received injection in the...
Axim® Biotechnologies Completes First Phase of Pharmacokinetic Clinical Study on Cannabinoid-Based Gum With Dronabinol
NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has completed the...
Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA Neurology. The JAMA...
resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update
-- Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB101 is well tolerated, crosses the blood brain barrier, and reaches concentrations in cerebrospinal fluid observed in preclinical models to inhibit the activity of TORC1 and induce...
Gilead Struggles to Recruit Patients for Coronavirus Drug Trial in China
On February 5, 2020, it was reported that clinical trials of Gilead Sciences’ remdesivir had launched in Wuhan, China. The experimental antiviral is to be evaluated as a treatment for 2019-nCoV, or what is now being called Covid-19. But there are now reports that the...
Greenphire and Roche Team to Address Critical Clinical Trial Patient Convenience Issues at 11th Annual SCOPE Summit
Companies to co-present survey findings on the direct impact of participant-centric initiatives on patient retention and trial success ORLANDO, Fla., Feb. 18, 2020 /PRNewswire/ -- Greenphire, the global leader in financial software for clinical trials, today announced...
Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643
CRANBURY, N.J., Feb. 19, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide...
Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that Bristol-Myers Squibb informed the company that the randomized Phase 2...
Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients With Atopic Dermatitis
Primary and secondary endpoints met in both TRuE-AD1 and TRuE-AD2 WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the second randomized, vehicle-controlled, pivotal Phase 3 study from the TRuE-AD clinical trial program has met its primary...
DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors
SAN DIEGO, Feb. 19, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced it has enrolled and begun dosing the final patient...
Itamar™ Medical Announces Publication of COMPASS Study Validating First Scoring Guidelines for WatchPAT™ Device in Diagnosing Sleep Apnea
Two additional published studies highlight WatchPAT’s accuracy and effectiveness in patients with Central Sleep Apnea (CSA) and Chronic Obstructive Pulmonary Disease (COPD) CAESAREA, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE:...
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
CLEVELAND, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin to optimize treatment for people living with diabetes, today announced...
ReNeuron Group plc – Positive Phase 2a stroke clinical data published
Positive Phase 2a stroke clinical data published ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a...
Boehringer-Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox
Boehringer Ingelheim offers MyStudyWindow to provide patients, families, caregivers, and doctors consistent access to information about Boehringer Ingelheim’s actively recruiting studies conducted at global site locations The platform features patient-centric study...
Axim® Biotechnologies Completes First Phase of Pharmacokinetic Clinical Study on Cannabinoid-Based Gum With Dronabinol
NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has completed the...
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet...